NANLING: Roxadustat Effectiveness/Safety in Chronic Kidney Disease-Associated Anemia with Peritoneal Dialysis
Roxadustat corrected anemia in Chinese patients with CKD on PD, irrespective of baseline T2DM. Adverse events were consistent with roxadustat's known safety profile and with PD patients' characteristics.
Institutions
- Central South University (CN)
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Zimmer Biomet (Netherlands) (NL)
- Peking University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Wuhan No.1 Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN)
- Peking University First Hospital (CN)
- FibroGen (United States) (US)
- Guangdong Academy of Medical Sciences (CN)
- Second Xiangya Hospital of Central South University (CN)
- Third Xiangya Hospital (CN)
- Wuhan No.9 Hospital (CN)
- Wuxi People's Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1159/000549723
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- FibroGen